or Try an Advanced Search...

    Technical Analysis for CGON - CG Oncology, Inc.

    Grade Last Price % Change Price Change
    F 31.57 4.36% 1.32
    CGON closed up 4.36 percent on Friday, June 28, 2024, on 1.56 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Down
    Historical CGON trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 4.36%
    Multiple of Ten Bullish Other 4.36%
    Down 3 Days in a Row Weakness 4.36%
    Lower Bollinger Band Touch Weakness 4.36%
    Oversold Stochastic Weakness 4.36%
    Older End-of-Day Signals for CGON ...

       Recent Intraday Alerts

    Alert Time
    Up 5% 1 day ago
    60 Minute Opening Range Breakout 1 day ago
    Possible NR7 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Gapped Up (Full) 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CGON Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Virotherapy Immunotherapies Oncolytic Virus

    Is CGON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 18 CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
    Jun 6 CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
    May 24 CG Oncology climbs 10% on Phase 2 data for bladder cancer drug
    May 24 CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
    May 13 CG Oncology upgraded by Goldman Sachs on recent clinical data
    May 9 CG Oncology, Inc. reports Q1 results
    May 9 CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
    May 6 CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
    May 3 CG Oncology reports data from Phase 3 bladder cancer study
    May 3 CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
    See more CGON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 50.23
    52 Week Low 25.77
    Average Volume 689,360
    200-Day Moving Average 0.00
    50-Day Moving Average 33.58
    20-Day Moving Average 33.59
    10-Day Moving Average 32.15
    Average True Range 2.12
    RSI (14) 44.13
    ADX 15.73
    +DI 15.84
    -DI 24.45
    Chandelier Exit (Long, 3 ATRs) 30.79
    Chandelier Exit (Short, 3 ATRs) 35.61
    Upper Bollinger Bands 37.33
    Lower Bollinger Band 29.86
    Percent B (%b) 0.23
    BandWidth 22.22
    MACD Line -0.73
    MACD Signal Line -0.38
    MACD Histogram -0.3531
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 33.15
    Resistance 3 (R3) 33.09 32.50 32.89
    Resistance 2 (R2) 32.50 32.09 32.53 32.80
    Resistance 1 (R1) 32.03 31.84 31.74 32.10 32.71
    Pivot Point 31.44 31.44 31.29 31.47 31.44
    Support 1 (S1) 30.98 31.04 30.68 31.04 30.43
    Support 2 (S2) 30.39 30.79 30.42 30.34
    Support 3 (S3) 29.92 30.39 30.25
    Support 4 (S4) 29.99